Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer

Alexander P. Glaser, Zhuqing Shi, Jun Wei, Nadia A. Lanman, Skylar Ladson-Gary, Renee E. Vickman, Omar E. Franco, Susan E. Crawford, S. Lilly Zheng, Simon W. Hayward, William B. Isaacs, Brian T. Helfand, Jianfeng XumedRxiv 2021 · DOI

TL;DR

This study provides strong evidence that Benign Prostatic Hyperplasia (BPH) and Prostate Cancer (PCa) share a common genetic foundation, debunking the long-held belief that their association is merely a result of "detection bias." Interestingly, while a high genetic risk for BPH correlates with an increased risk of developing prostate cancer, it is significantly associated with a lower risk of the cancer being lethal.

What Problem Does This Paper Address?

For decades, the medical community has debated whether BPH (non-cancerous prostate enlargement) and PCa (malignant growth) are linked. While observational studies often show they occur together, many experts—including the National Cancer Institute—attribute this to "detection bias." The logic is simple: men seeking treatment for BPH symptoms are more likely to undergo thorough prostate exams and PSA testing, leading to more frequent (but perhaps incidental) cancer diagnoses.

Because SNPs (Single Nucleotide Polymorphisms) are fixed at conception, they are immune to this detection bias. By looking at the "genetic architecture" of both diseases, the authors aimed to determine if there is a true biological link between these two common conditions or if the correlation is just a statistical artifact of clinical practice.

Methods

The researchers utilized data from the UK Biobank (UKB), focusing on three levels of analysis:

  1. Phenotypical Correlation: A standard statistical check (chi-square) to see how often the diseases co-occur in the population.
  2. Genetic Correlation ($r_g$): Using Linkage Disequilibrium Score Regression (LDSR) on over 1.1 million SNPs across the entire genome to estimate the overlap in heritability.
  3. Cross-Disease Genetic Risk Scores (GRS): The authors took known risk-associated SNPs for one disease (15 for BPH and 239 for PCa) and tested if they could predict the other disease. This "cross-testing" is a powerful way to identify shared biological pathways.

Datasets

The study relied on the UK Biobank, specifically a cohort of 214,717 White men.

  • BPH cases: 24,623 (11.47%)
  • PCa cases: 14,311 (6.67%)
  • Lethal PCa: Identified via death registries.

The researchers also performed a comparative analysis with bladder cancer as a "negative control" to ensure their methods weren't just picking up general urological screening biases.

Key Insights and Ideas

  • The Link is Real: The study found a significant genetic correlation ($r_g = 0.27$). This confirms that BPH and PCa aren't just neighbors in the prostate; they share a significant portion of their underlying genetic "blueprint."
  • The Lethal Paradox: One of the most surprising findings was that a high Genetic Risk Score for BPH ($GRS_{BPH}$) was inversely associated with lethal prostate cancer ($OR = 0.58$). In other words, the same genetics that make a man more likely to have an enlarged prostate might actually protect him from the most aggressive forms of prostate cancer.
  • Validation via Bladder Cancer: When the authors looked at BPH and bladder cancer, they found a high phenotypical correlation (likely due to detection bias) but zero genetic correlation. This contrast strongly suggests that the BPH-PCa link is uniquely biological.
  • Pleiotropy or Proximity? The shared risk likely comes from either pleiotropy (one gene affecting both diseases) or linkage disequilibrium (different genes for each disease located very close to each other on the chromosome).

Key Results

  • Genetic Correlation: $r_g = 0.27$ ($P = 9.17E-06$), indicating a substantial shared genetic basis.
  • Cross-Disease Prediction: 51 out of 250 established risk SNPs for one disease were significantly associated with the other—far more than would happen by chance.
  • Risk Stratification: Men with high genetic risk scores for both BPH and PCa had a significantly higher prevalence of both diseases (3.76%) compared to those with low scores (1.19%).
  • Lethal PCa Protection: Men in the highest decile of BPH genetic risk had a lethal PCa prevalence of only 0.23%, compared to 0.33% in the remaining groups.

Limitations and Future Work

  • Population Diversity: The study was limited to White men in the UK Biobank (~95% of the cohort). The authors acknowledge that these findings need to be validated in more diverse ethnic and racial populations.
  • Clinical Granularity: The UK Biobank lacks some granular clinical data, such as specific prostate volumes, Gleason grades at diagnosis, or longitudinal PSA measurements, which could provide more insight into the "Lethal Paradox."
  • Functional Mechanisms: While the study identifies that a link exists, it doesn't explain how these SNPs function biologically. Future research is needed to perform functional analyses on the shared chromosomal regions to understand the exact molecular pathways involved.
  • Policy Implications: The authors suggest that current medical guidelines stating BPH and PCa are unrelated may need to be reconsidered in light of this genetic evidence.

Summary updated

Abstract

Abstract Background The association between benign prostatic hyperplasia (BPH) and prostate cancer (PCa) remains controversial, largely due to inherent detection bias in traditional observational studies. The objective of this study is to assess their association using inherited SNPs. Methods Subjects were White men from the large population-based UK Biobank (UKB). Association between BPH and PCa was tested: 1) phenotypical correlation using chi-square test, 2) genetic correlation ( r g ) based on 1,126,841 polymorphic SNPs across the genome using linkage disequilibrium score regression (LDSR), and 3) cross-disease genetic associations based on known risk-associated SNPs (15 for BPH and 239 for PCa), individually and cumulatively as measured by genetic risk score (GRS). Findings Among 214,717 White men in the UKB, 24,623 (11.47%) and 14,311 (6.67%) had a diagnosis of BPH and PCa, respectively. Diagnoses of these two diseases were significantly correlated, χ 2 =1862.80, P <1E-299. A significant genetic correlation was found, r g (95% confidence interval (CI))=0.27 (0.15-0.39), P =9.17E-06. In addition, significant cross-disease genetic associations for established risk-associated SNPs were also found. Among the 250 established GWAS-significant SNPs of PCa or BPH, 51 were significantly associated with risk of the other disease at P <0.05, significantly more than expected by chance (N=12), P =3.04E-7 ( χ 2 -test). Furthermore, significant cross-disease GRS associations were also found; GRS BPH was significantly associated with PCa risk (odds ratio (OR)=1.26 (1.18-1.36), P =1.62E-10), and GRS PCa was significantly associated with BPH risk (OR=1.03 (1.02-1.04), P =8.57E-06). Moreover, GRS BPH was significantly and inversely associated with lethal PCa risk in a PCa case-case analysis (OR=0.58 (0.41-0.81), P =1.57E-03). In contrast, GRS PCa was not significantly associated with lethal PCa (OR=0.99 (0.94-1.04), P =0.79). Interpretation BPH and PCa share common inherited genetics which suggests the phenotypical association of these two diseases in observational studies is not entirely caused by detection bias. This novel finding may have implications in disease etiology and risk stratification. Funding None.
BibTeX
@misc{glaser2021shared,
  author = {Alexander P. Glaser and Zhuqing Shi and Jun Wei and Nadia A. Lanman and Skylar Ladson-Gary and Renee E. Vickman and Omar E. Franco and Susan E. Crawford and S. Lilly Zheng and Simon W. Hayward and William B. Isaacs and Brian T. Helfand and Jianfeng Xu},
  title = {{Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer}},
  year = {2021},
  doi = {10.1101/2021.12.10.21267604},
  howpublished = {medRxiv},
}
Figure